EXHIBIT 19


                 [LETTERHEAD OF CAMBRIDGE ANTIBODY TECHNOLOGY]

Dr David Ebsworth
Danziger Strasse 17
51491 Overath
Germany

                                                                 22 January 2003

Dear Dr Ebsworth

Service Agreement with Oxford Glycosciences plc

We are writing to you in relation to the proposed merger of Oxford Glycosciences
plc with Cambridge Antibody Technology Group plc ("the Merger"), which is
proposed to be effected by a scheme of arrangement pursuant to section 425 of
the Companies Act 1985.

Subject to the Merger becoming effective by 30 April 2003:

(a)   we would propose that Clause 20.1 of your service agreement with Oxford
      Glycosciences plc dated 22 May 2002 ("the Service Agreement") be varied by
      increasing the period within which you are required to give notice of
      termination of your employment following the Merger in accordance with
      that clause from 30 days to 12 months following the date upon which the
      Merger becomes effective;

(b)   in consideration of this, you agree (without prejudice to your continuing
      employment with Oxford Glycosciences plc) at our request made at any time
      to resign promptly from the board of Oxford Glycosciences plc and from the
      board of any member of the Oxford Glycosciences group of companies without
      any claim against Oxford Glycosciences plc or any of the members of the
      Oxford Glycosciences group of companies, whether in relation to your
      employment with or office as a director of such companies, arising from
      such resignations. Should you fail to do so, the board of Cambridge
      Antibody Technology Group plc shall be irrevocably authorised to appoint
      some person in your name and on your behalf to sign any documents and take
      such other steps as are necessary to give effect to such resignations.

For the avoidance of doubt, the above variation would apply only to the Merger
and not to any other change of control that may take place after the Merger has
been implemented.

We should be grateful if you would confirm your agreement to the proposed
variation by executing this letter below. This letter may be executed in
counterparts and by the parties to it on separate counterparts, each of which
when so executed and delivered shall be an original, but both counterparts shall
together constitute one and the same instrument.





EXECUTION:

Dated 22 January 2003

SIGNED AND DELIVERED as a DEED by                 )     /s/ JOHN ASTON
JOHN ASTON, Director and DIANE MELLETT,           )
Secretary duly authorised for and on behalf of    )     /s/ DIANE MELLETT
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC           )

SIGNED AND DELIVERED as a DEED by DAVID           )     /s/ DAVID EBSWORTH
EBSWORTH in the presence of                       )

Witness' signature                     /s/ Graham Gibb
                                -------------------------------
Witness' name (in capitals)              GRAHAM GIBB
                                -------------------------------
Witness' Address                ONE BUNHILL ROW LONDON EC1Y 8YY
                                -------------------------------
Occupation:                               SOLICITOR
                                -------------------------------